IP Library Granted Patent US 12,188,089
Granted Patent B2
US 12,188,089 · App. 18/439,062 · Granted Jan 7, 2025

Cleavable disulfide linkers and uses thereof

Inventors: Ronald Graham (Carlsbad, CA); Megha Cila (San Diego, CA)
Assignee: Singular Genomics Systems, Inc.
C12Q1/6874C07H19/10C07H19/20C12Q1/6876C12Q1/6806
View Patent ↗
Loading inventors, assignments & file history…
Monitor This Case
Get email alerts when status or documents change.
Order Certified Copies
Most orders are placed with the USPTO same day — all within 24 business hours.
Order via The Patent Place →
Pre-filled with this patent's details
Quick Facts
Patent No.
US 12,188,089
App. No.
18/439,062
Granted
Jan 7, 2025
Kind
B2
Abstract

Disclosed herein, inter alia, are methods and cleavable compounds that minimize byproduct formation following cleavage.

Claims (35)

1. A method of incorporating a compound into a primer, the method comprising:

(i) contacting a primer with a compound, wherein said primer is hybridized to a nucleic acid molecule in a cell or tissue, wherein the compound comprises a detectable label attached thereto via a divalent linker, L 100 , wherein L 100 comprises the formula:

wherein R 5 and R 6 are independently unsubstituted alkyl, —CN, —OH, —NH 2 , —COOH, —CONH 2 , —NO 2 , —SO 3 H, —SO 4 H, —SO 2 NH 2 , —NHNH 2 , —ONH 2 , substituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl; and W 1 and W 2 are —O—; and

(ii) incorporating with a polymerase the compound into the primer.

2. The method of claim 1 , wherein the cell or tissue is within a flow cell.

3. The method of claim 1 , wherein the cell or tissue is immobilized to a well of a microplate.

4. The method of claim 1 , prior to step (i), hybridizing a polynucleotide probe to an RNA molecule and amplifying the polynucleotide probe to form the nucleic acid molecule.

5. The method of claim 4 , further comprising hybridizing the primer to the nucleic acid molecule.

6. The method of claim 1 , further comprising cleaving the divalent linker with a reducing agent.

7. The method of claim 1 , further comprising detecting the detectable label of the incorporated compound following step (ii).

8. The method of claim 7 , further comprising repeating steps (i) and (ii) to sequence the nucleic acid molecule.

9. The method of claim 7 , wherein detecting comprises detecting an emission wavelength from the detectable label.

10. The method of claim 1 , wherein the compound has the formula:

wherein R 3 is a reversible terminator moiety, hydrogen, substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl;

R 4 is a detectable moiety;

L 100 has the formula:

wherein

L 1 has the formula -L 101 -L 102 -L 103 -;

L 101 , L 102 , and L 103 are independently a bond, —NH—, —O—, —C(O)—, —C(O) NH—,

—NHC(O)—, —NHC(O) NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene;

L 2 has the formula -L 201 -L 202 -L 203 -; and

L 201 , L 202 , and L 203 are independently a bond, —NH—, —O—, —C(O)—, —C(O) NH—,

—NHC(O)—, —NHC(O) NH—, —C(O)O—, —OC(O)—, substituted or unsubstituted alkylene, substituted or unsubstituted heteroalkylene, substituted or unsubstituted cycloalkylene, substituted or unsubstituted heterocycloalkylene, substituted or unsubstituted arylene, or substituted or unsubstituted heteroarylene.

11. The method of claim 1 , wherein R 5 and R 6 are independently substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, or substituted or unsubstituted heteroaryl.

12. The method of claim 1 , wherein R 5 and R 6 are unsubstituted alkyl.

13. The method of claim 1 , wherein R 5 and R 6 are unsubstituted methyl, unsubstituted ethyl, unsubstituted isopropyl, or unsubstituted n-propyl.

14. The method of claim 1 , wherein L 100 has the formula:

15. The method of claim 1 , wherein L 100 has the formula:

16. The method of claim 1 , wherein L 100 has the formula:

17. The method of claim 1 , wherein the compound has the formula:

18. The method of claim 1 , wherein the compound has the formula:

19. The method of claim 10 , wherein R 3 is a reversible terminator moiety comprising:

20. The method of claim 10 , wherein R 3 is

wherein R 7 is substituted or unsubstituted alkyl, substituted or unsubstituted heteroalkyl, substituted or unsubstituted cycloalkyl, substituted or unsubstituted heterocycloalkyl, substituted or unsubstituted aryl, substituted or unsubstituted heteroaryl; and

R 8 is substituted or unsubstituted alkyl.

Assignments (2)
SECURITY INTEREST Recorded Mar 7, 2025
From: SINGULAR GENOMICS SYSTEMS, INC.
To: FIRST-CITIZENS BANK & TRUST COMPANY
Reel/Frame 070440/0465 →
ASSIGNMENT OF ASSIGNOR'S INTEREST Recorded May 20, 2024
From: GRAHAM, RONALD; CILA, MEGHA
To: SINGULAR GENOMICS SYSTEMS, INC.
Reel/Frame 067469/0676 →
Continuity (6)
Continuation 18449601 · Aug 14, 2023
Continuation PCTUS2022052357 · Dec 9, 2022
Provisional Application 63311607 · Feb 18, 2022
Provisional Application 63301775 · Jan 21, 2022
Provisional Application 63288369 · Dec 10, 2021
Related Publication 20240327907A1 · Oct 3, 2024
References Cited (47)
US 5872244A · Hiatt et al. · 1999 [cited by applicant]
US 6214987B1 · Hiatt et al. · 2001 [cited by applicant]
US 6664079B2 · Ju et al. · 2003 [cited by applicant]
US 10738072B1 · Graham et al. · 2020 [cited by applicant]
US 10822653B1 · Graham et al. · 2020 [cited by applicant]
US 11174281B1 · Graham et al. · 2021 [cited by applicant]
US 11946103B2 · Graham · 2024 [cited by examiner]
US 20020064782A1 · Shinoki et al. · 2002 [cited by applicant]
US 20110014611A1 · Ju et al. · 2011 [cited by applicant]
US 20120156671A1 · Liu et al. · 2012 [cited by applicant]
US 20130264207A1 · Ju et al. · 2013 [cited by applicant]
US 20160108382A1 · Efcavitch et al. · 2016 [cited by applicant]
US 20160355541A1 · Jain et al. · 2016 [cited by applicant]
US 20170137869A1 · Marma et al. · 2017 [cited by applicant]
US 20170166961A1 · Liu et al. · 2017 [cited by applicant]
US 20180274024A1 · Ju et al. · 2018 [cited by applicant]
US 20180274025A1 · Marma et al. · 2018 [cited by applicant]
US 20190077726A1 · Graham et al. · 2019 [cited by applicant]
US 20200283467A1 · Liu et al. · 2020 [cited by applicant]
US 20220127299A1 · Graham et al. · 2022 [cited by applicant]
US 20230002436A1 · Graham et al. · 2023 [cited by applicant]
US 20230028359A1 · Graham et al. · 2023 [cited by applicant]
US 20230203083A1 · Graham et al. · 2023 [cited by applicant]
EP 3870593A1 · 2021 [cited by applicant]
EP 3908286A1 · 2021 [cited by applicant]
EP 4117682A1 · 2023 [cited by applicant]
WO WO2017058953A1 · 2017 [cited by applicant]
WO WO2017079498A2 · 2017 [cited by applicant]
WO WO2017176679A1 · 2017 [cited by applicant]
WO WO2020069424A1 · 2020 [cited by applicant]
WO WO2020086834A1 · 2020 [cited by applicant]
WO WO2020146397A1 · 2020 [cited by applicant]
WO WO2021216998A1 · 2021 [cited by applicant]
Bentley, D. R. et al. (Nov. 6, 2008). “Accurate whole human genome sequencing using reversible terminator chemistry,” [cited by applicant]
Chen, F. et al. (Feb. 2013, e-published Jan. 23, 2013). “The history and advances of reversible terminators used in new generations of sequencing technology,” [cited by applicant]
Extended European Search Report mailed on Oct. 19, 2019, for EP Patent Application No. 19875948.2, 15 pages. [cited by applicant]
Extended European Search Report mailed on Sep. 8, 2022, for EP Patent Application No. 20738590.7, 10 pages. [cited by applicant]
Guillier, F. et al. (Jun. 1, 2000, e-published May 6, 2000). “Linkers and cleavage strategies in solid-phase organic synthesis and combinatorial chemistry,” [cited by applicant]
Guo, J. et al. (Jul. 8, 2008, e-published Jun. 30, 2008). “Four-color DNA sequencing with 3′-O-modified nucleotide reversible terminators and chemically cleavable fluorescent dideoxynucleotides,” [cited by applicant]
Hutter, D. et al. (Nov. 2010, e-published Dec. 1, 2010). “Labeled nucleoside triphosphates with reversibly terminating aminoalkoxyl groups,” [cited by applicant]
International Search Report and Written Opinion mailed on Jan. 6, 2020, for PCT application PCT/US2019/057842, filed Oct. 24, 2019, 14 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Apr. 2, 2020, for PCT application PCT/US2020/012595, filed Jan. 7, 2020, 6 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Sep. 8, 2021, for PCT application PCT/US2021/028839, filed Apr. 21, 2021, 6 pages. [cited by applicant]
International Search Report and Written Opinion mailed on Jun. 13, 2023, for PCT application PCT/US2022/052357, filed Dec. 9, 2022, 12 pages. [cited by applicant]
Ju, J. et al. (Dec. 26, 2006). “Four-color DNA sequencing by synthesis using cleavable fluorescent nucleotide reversible terminators,” [cited by applicant]
Ruparel, H. et al. (Apr. 26, 2005, e-published Apr. 13, 2005). “Design and synthesis of a 3′-O-allyl photocleavable fluorescent nucleotide as a reversible terminator for DNA sequencing by synthesis,” [cited by applicant]
Wu, J. et al. (Oct. 16, 2007, e-published Oct. 8, 2007). “3′-O-modified nucleotides as reversible terminators for pyrosequencing,” [cited by applicant]
Cited By (1)
US 12,577,271